BRIM Biotechnology (TPE:6885) Stock Based Compensation: NT$34.13 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6885 BRIM Biotechnology Inc TPE:6885
40 GF Score
Price NT$20.55
GF Value NT$707.93
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is BRIM Biotechnology Stock Based Compensation?

BRIM Biotechnology TPE:6885 +0.98% 40 Stock Based Compensation is NT$34.13 Mil as of Jun. 2026. GuruFocus rates TPE:6885 with a GF Score™ of 40/100 and a GF Value™ of NT$707.93 (Possible Value Trap). The stock has 3 warning signs investors should review.

BRIM Biotechnology's Stock Based Compensation for the three months ended in Jun. 2026 was NT$9.31 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was NT$34.13 Mil.

BRIM Biotechnology Stock Based Compensation Related Terms

BRIM Biotechnology Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for BRIM Biotechnology's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BRIM Biotechnology Stock Based Compensation Chart

BRIM Biotechnology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 7.07 35.32 47.78 39.17 36.02

BRIM Biotechnology Quarterly Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.45 9.92 12.54 2.37 9.31
TPE:6885
40GF Score
BRIM Biotechnology Inc TPE:6885
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BRIM Biotechnology Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$34.13 Mil.

What does a Stock Based Compensation of NT$34.13 Mil mean?
BRIM Biotechnology (TPE:6885) has a Stock Based Compensation of NT$34.13 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for BRIM Biotechnology and its competitors.
Is BRIM Biotechnology's Stock Based Compensation too high?
BRIM Biotechnology's current Stock Based Compensation is NT$34.13 Mil. Overall, BRIM Biotechnology has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BRIM Biotechnology's Stock Based Compensation compare to VRTX and REGN?
BRIM Biotechnology's Stock Based Compensation of NT$34.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for BRIM Biotechnology and its competitors. BRIM Biotechnology's current Stock Based Compensation is NT$34.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRIM Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, BRIM Biotechnology (TPE:6885) is currently considered Possible Value Trap. The stock's GF Value™ is NT$707.93, compared to a current price of NT$20.55 — trading 97.1% below its estimated fair value. The current Stock Based Compensation is NT$34.13 Mil. BRIM Biotechnology's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For BRIM Biotechnology (TPE:6885), the current Stock Based Compensation is NT$34.13 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BRIM Biotechnology (TPE:6885) Overvalued in 2026?

Based on GuruFocus' analysis, BRIM Biotechnology stock appears to be undervalued. The current stock price of NT$20.55 is trading 97.1% below its estimated GF Value™ of NT$707.93. GuruFocus considers BRIM Biotechnology to be Possible Value Trap.

Key valuation signals for TPE:6885:

  • Stock Based Compensation: NT$34.13 Mil
  • GF Value™: NT$707.93 vs. price of NT$20.55 (97.1% below fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the TPE:6885 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BRIM Biotechnology Business Description

Address Alley 30, Lane 358, Ruiguang Road, 8th Floor, No.1, Neihu District, Taipei, TWN, 11492
BRIM Biotechnology Inc is engaged in the research and development of new drug translation, genetic testing services, research and development services in natural and engineering sciences, and medical laboratory services. The Group has two reportable operating segments: BRIM's main business is new drug translational development services, and Compass's main business is gene sequencing and testing technology services. It generates the majority of its revenue from the BRIM segment. Geographically, it operates in Taiwan, Japan, and the USA. It generates the majority of its revenue from Taiwan.
40GF Score

Get the complete analysis for TPE:6885

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$20.55
Price
NT$707.93
GF Value